不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel:ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:T and NK lymphoblastic leukemia/lymphoma: Report from the 2023 SH/EAHP Workshop.
T and NK lymphoblastic leukemia/lymphoma: Report from the 2023 SH/EAHP Workshop.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
本次会议重点讨论了表达细胞毒性标志物、/表型、更成熟免疫表型的罕见 T-LBL/L 病例,以及难以分类的 ALAL。在 T-ALL 病例中,发现了有趣的复发变化,其中 1 例患者出现了成熟 NK 细胞表型。ALAL 患者表现为既往治疗或胚系突变这一不寻常的背景。
2023年血液病理学会/欧洲血液病理学协会研讨会讨论了T细胞和自然杀伤(NK)细胞淋巴瘤/白血病诊断和分类的进展。
第8场研讨会收集了38例未成熟T细胞和NK细胞淋巴瘤/白血病、谱系不明急性白血病(ALAL)以及其他杂类病例,包括惰性T淋巴母细胞增殖。
20例T淋巴母细胞白血病/淋巴瘤(T-LBL/L)患者和3例早期T细胞前体急性淋巴细胞白血病(ETP-ALL)患者的中位年龄为21.5岁。男性占优势(占所有病例的70%),40%有纵隔肿块。60%的病例CD34和TdT均为阴性。此外,提交了7例ALAL和3例混合表型急性白血病T/髓系亚型,中位发病年龄为16岁(范围11-56岁),大多数患者(67%)常表现为淋巴结肿大或脾肿大。还提交了1例NK急性淋巴细胞白血病。
The 2023 Society for Hematopathology/European Association for Hematopathology Workshop addressed advancements in the diagnosis and classification of T- and natural killer (NK)-cell lymphomas/leukemias.
Session 8 of the workshop collected a diverse set of 38 cases of immature T- and NK-cell lymphoma/leukemias, as well as acute leukemia of ambiguous lineage (ALAL) and other miscellaneous cases, including indolent T-lymphoblastic proliferations.
Twenty patients with T-lymphoblastic leukemia/lymphoma (T-LBL/L) and 3 patients with early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) presented at a median age of 21.5 years. Male sex was predominant (70% of all cases), with 40% having a mediastinal mass. Cases (60%) were negative for both CD34 and TdT. In addition, 7 ALAL and 3 mixed phenotype acute leukemia, T/myeloid subtypes were submitted with a median presenting age of 16 (range, 11-56) years, and most patients (67%) frequently showed adenopathy or splenomegaly. A single case of NK acute lymphoblastic leukemia was also submitted.
This session highlighted unusual T-LBL/L cases with expression of cytotoxic markers, / phenotype, a more mature immunophenotype, and ALAL that are challenging to classify. Among T-ALL cases, interesting relapse changes were identified, with 1 patient developing a mature NK-cell phenotype. Patients with ALAL presented in an unusual setting of prior therapy or a germline mutation.
MEMBER ACCOUNT
登录成功会直接打开下一页。